Astrazeneca (AZN) Change in Cash (2009 - 2026)

Astrazeneca has reported Change in Cash for 18 years, with the latest figure at -$1.9 billion in Q2 2026.

• On a quarterly basis, Change in Cash fell 214.3% year-over-year to -$1.9 billion in Q2 2026; TTM through Jun 2026 was $4.3 billion, a 62.61% decrease from a year earlier, with the FY2025 full-year figure at $5.7 billion, up 1.08% from the prior year.
• Change in Cash was -$1.9 billion for Q2 2026 at Astrazeneca, down from $7.6 billion in the prior quarter.
• The five-year high for Change in Cash was $7.8 billion in Q1 2024, with the low at -$6.7 billion in Q2 2024.
• Average Change in Cash over 5 years is $2.4 billion, with a median of $3.1 billion recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Change in Cash slumped 2610.44% in 2024, then surged 124.14% in 2025.
• Over 5 years, Change in Cash stood at $6.0 billion in 2022, then sank by 104.12% to -$249.0 million in 2023, then jumped by 1925.3% to $4.5 billion in 2024, then tumbled by 153.8% to -$2.4 billion in 2025, then increased by 23.84% to -$1.9 billion in 2026.
• The last three Change in Cash figures came in at -$1.9 billion (Q2 2026), $7.6 billion (Q1 2026), and -$2.4 billion (Q4 2025), per Business Quant data.